Sun, Dec 21, 2014, 8:31 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • troyanderson747 troyanderson747 Oct 11, 2012 10:01 AM Flag

    NeuVax worht BILLIONS and $4.00 target reiterated ...again

    Roughly 200 female patients were treated during the two phase 2 studies for NeuVax, and those who received the vaccine saw a 50% reduction in recurrence. The vaccine was even more effective when booster doses were utilized. This indicates that the vaccine can be used in several different ways, and thus, increases its market potential. The potential for billions in annual revenue resulted in one of the world's best-known capital markets investment banks, Cantor Fitzgerald, reiterating its "Buy" rating and a $4.00 price target for Galena Biopharma.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.57-0.05(-3.09%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.